CEL-SCI Corporation (NYSE American: CVM) announced it is launching a global confirmatory registration study of its investigational drug Multikine (Leukocyte ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE